Lars Hytting

Lars Hytting

investor Unknown

Lars Hytting is an investor at ArthaScope, known for his insights into the pharmaceutical market. Recently, he commented on the unexpected drop in Novo Nordisk's share price, indicating that even the most skeptical analysts did not anticipate such a significant decline, highlighting the intense competition in the weight-loss drug sector.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
23,394
Power
1,266$
Sentiment
5.00
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Australia 1 5.00 0.09% +0% 25,499,884 23,394 $1,380,000 1,266$
Totals 1 25,499,884 23,394 $1,380,000 1,266$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Australia Australia: Investor ArthaScope’s Lars Hytting told Bloomberg that even the most sceptical analyst didn’t anticipate this big a drop. 5

The Sydney Morning Herald: Ozempic maker Novo Nordisk faces heavy competition from Mounjaro and other weight loss drugs in Australia